How Tesamorelin's Peptide Class Is Described in Catalogues

Research catalogues rarely describe tesamorelin the same way twice, and understanding how tesamorelin’s peptide class is described in research catalogues starts with recognizing that suppliers borrow language from several overlapping systems: pharmacological class, receptor target, structural family, and regulatory category. A single listing might call the same vial a “GHRH analog,” a “growth hormone-releasing peptide,” and a “synthetic 44-amino acid sequence” in three different fields on the same page. None of these labels are wrong. They describe the molecule from different angles, and knowing which angle a catalogue is using makes the listing easier to read correctly.

The Core Classification: GHRH Analog

The most consistent term across catalogues is “growth hormone-releasing hormone (GHRH) analog.” This places tesamorelin in a structural and functional family with the naturally occurring GHRH peptide, modified to resist rapid breakdown. Catalogues that lead with this term are describing mechanism of class, not a claim about what the compound does in a person. The GHRH designation tells a reader that the molecule is built to interact with the GHRH receptor family, which sits upstream of the broader growth hormone and IGF-1 signaling axis studied extensively in endocrine literature.

This is one part of how tesamorelin’s peptide class is described in research catalogues that stays fairly consistent from vendor to vendor. Some catalogues instead use the broader label “growth hormone secretagogue,” a category that also includes ghrelin-mimetic peptides with a different receptor target. This is where class language can get confusing: two peptides listed under “secretagogue” on the same site may act through entirely different receptors. A catalogue that distinguishes “GHRH-receptor agonist” from “ghrelin-receptor agonist” within its secretagogue category is giving more precise structural information than one that lumps everything together.

Structural and Molecular Descriptors

Beyond the pharmacological class, catalogues typically list a set of molecular descriptors that identify the exact compound rather than the category it belongs to:

Descriptor	What It Communicates
Sequence length (44 amino acids)	Confirms the peptide backbone matches the tesamorelin structure, not a truncated fragment
CAS registry number	A unique identifier for the specific chemical entity, used to cross-reference across suppliers
Molecular formula and weight	Lets a reader verify purity calculations and confirm the listing matches the registered compound
Synonym field (e.g., “TH9507”)	Maps the catalogue entry to the compound’s development-stage name used in earlier research literature

Listings that include all four descriptors are generally easier to verify against independent references, since the sequence length and molecular weight can be checked against published structural data rather than taken on faith from a single vendor’s page.

Where “Synthetic” and “Research-Grade” Fit In

Two more words appear in nearly every catalogue entry: “synthetic” and “research-grade” (or “research use only”). “Synthetic” describes how the peptide is produced, typically via solid-phase synthesis, as opposed to being extracted from a biological source. “Research-grade” is a purity and handling designation, not a class descriptor. Catalogues sometimes place these terms next to the GHRH-analog classification in a way that makes them look like part of the same taxonomy, but they answer different questions: one is about origin and manufacturing method, the other is about the compound’s identity and mechanism family.

Confusing these categories is a common source of miscommunication between buyers and sellers. A listing can be accurately described as a “synthetic GHRH analog” while saying nothing about the analytical rigor behind its stated purity, and a separate certificate of analysis (COA) is the document that actually substantiates a purity figure, not the classification language itself.

Why Catalogue Language Diverges Across Suppliers

Not every supplier catalogue uses identical terminology, and the divergence is rarely arbitrary. Some catalogues are organized around receptor pharmacology and group compounds by target (GHRH receptor, GH secretagogue receptor, and so on). Others are organized around chemical family and group compounds by synthesis method or sequence homology. A few organize primarily by intended research application, sorting compounds under headings like “growth axis research” or “metabolic research,” which says more about how the catalogue is indexed than about the molecule’s structure.

This divergence is exactly why how tesamorelin’s peptide class is described in research catalogues can look inconsistent at first glance, even when every listing is technically accurate. Comparing listings across multiple catalogues is useful before treating any single description as definitive. A compound consistently described as a GHRH analog with a matching 44-amino-acid sequence and CAS number across several independent catalogues is easier to cross-verify than one where the classification language shifts from listing to listing without a matching molecular formula.

Reading Class Language Without Overinterpreting It

Classification terms describe structure and mechanism family. They are not a summary of outcomes, and a catalogue entry that classifies tesamorelin as a GHRH analog is not making a claim about results in any individual. The endocrine literature on the GH/IGF-1 axis illustrates why this distinction matters: the same axis has been studied across contexts as different as intrauterine growth patterns, circadian regulation, and extra-hepatic tissue effects, and the mechanism-level classification of a GHRH analog does not, by itself, predict which of those research contexts a given study addresses. A review of GH/IGF-1 axis disruption in animal models illustrates how broad this signaling network is, spanning skeletal, metabolic, and tissue-level pathways well beyond any single classification label (see the 2024 review of GH/IGF-1 axis disruption and GHRH receptor signaling models). Circadian regulation research on the same axis shows a similar pattern, with GH/IGF-1 signaling varying by time of day in ways that are independent of how a compound is classified in a catalogue (see the 2021 review of the GH-IGF-1 axis and circadian rhythm).

Catalogue entries that describe extra-hepatic or tissue-specific GH receptor activity draw on a separate body of literature entirely, underscoring that “GHRH analog” is a starting point for locating relevant research, not a complete description of every downstream pathway the axis touches (see the review of extra-hepatic acromegaly and GH receptor activity). Developmental research on the same axis, such as work examining intrauterine growth patterns, further demonstrates how the GH/IGF-1 signaling system has been studied across life stages that have nothing to do with a supplier’s classification taxonomy (see the 2009 review of GH/IGF-1 axis changes in intrauterine growth restriction).

Summary

How tesamorelin’s peptide class is described in research catalogues depends on which taxonomy a given supplier uses: pharmacological class (GHRH analog), receptor target (GHRH-receptor agonist within the broader secretagogue category), or structural descriptors (sequence length, CAS number, molecular formula). None of these labels substitute for a certificate of analysis, and none of them describe outcomes. Reading a catalogue entry carefully means separating the classification language from the purity documentation, and cross-checking molecular descriptors across more than one listing before treating any single catalogue’s terminology as the final word.